Navigation Links
PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Date:12/4/2009

s, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, unexpected financial obligations that could increase the rate of our cash consumption, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional research work, non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for the Company's lyophilized 3G rPA anthrax vaccine candidate. At this point there can be no assurance that this product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

SOURCE PharmAthene, Inc.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... 1,500 investor-families have received permanent green cards (I-829 petition approval) from the USCIS ... petition is the final step of the EB-5 visa process for immigrant investors ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care is ... Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing routine ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented peels ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... send information about new patients directly from Practice Perfect to FOTO enabling cost ... entry. , Steven Presement, President of Practice Perfect, stated "FOTO ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices In ... a look at the topic of arthritis. There are over 100 different types of ... arthritis types and statistics in an effort to shed light on this important topic. ...
(Date:9/1/2015)... ... 2015 , ... Curly Hair Solutions™ is thrilled to partner ... partnership between Curly Hair Solutions™ and Trade Secrets allows for nationwide distribution of ... Curly Hair Solutions™ team could not be more delighted to see their line ...
Breaking Medicine News(10 mins):Health News:CanAm Enterprises Reaches Another Milestone with More Than 1,500 I-829 Petition Approvals 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:Curly Hair Solutions™ Partners With Trade Secrets 2
... 2011 -- The American College of Physicians (ACP) is ... ACP InternistWeekly have won awards for excellence in publishing. ... Association Media & Publishing in the Newspapers: Feature Article: ... monitoring and a silver award for Best How-To Article ...
... 2011) Medical imaging facilities can now submit anonymized dose ... Registry (DIR) allowing them to compare their dose indices ... to national benchmarks. Participating facilities receive periodic feedback comparing their ... necessary adjustments to lower dose received from scans. ...
... new study by the NYU Cancer Institute, an NCI-designated ... leukemia, a type of blood cancer that affects children ... an intracellular communication pathway called Notch led to the ... this disease. Notch has already been implicated in another ...
... State University shows that the vast majority of patients at ... job of taking statins as prescribed. That,s especially unfortunate, because ... the quality and length of those patients, lives. "We ... prescribed statins are taking their prescribed dose on a regular ...
... May 12 (HealthDay News) -- Music hath charms to protect ... by Northwestern University researchers who compared adults aged 45 to ... appears to confer advantages in at least two important functions ... to hear speech in noise," study co-author Nina Kraus, director ...
... passed 20 years ago, the American Disabilities Act offered ... disabilities, but differences still exist. Barring people with ... of the blame, and researchers from Case Western Reserve ... change that restriction. In a commentary for ...
Cached Medicine News:Health News:ACR launches dose index registry 2Health News:Study reveals origins of a cancer affecting the blood and bone marrow 2Health News:Study: Most at-risk patients don't adhere to statin treatment, despite real benefits 2Health News:Musicians Maintain Memory, Hearing as They Age 2Health News:CWRU researchers call for changing how research is done 2